- Home
- IMVT
IMVT
Immunovant Inc.
as of 12-05-2025 3:45pm EST
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 4.0B | IPO Year: | N/A |
| Target Price: | $27.71 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.72 - $29.49 | Next Earning Date: | 11-10-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered IMVT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
Director
Avg Cost/Share
$23.55
Shares
22,249
Total Value
$517,189.24
Owned After
88,750
Director
Avg Cost/Share
$23.55
Shares
15,000
Total Value
$348,665.38
Owned After
120,773
Chief Operating Officer
Avg Cost/Share
$23.76
Shares
12,626
Total Value
$298,237.29
Owned After
175,886
Chief Medical Officer
Avg Cost/Share
$19.03
Shares
2,595
Total Value
$49,382.85
Owned After
217,958
SEC Form 4
Chief Technology Officer
Avg Cost/Share
$19.03
Shares
2,520
Total Value
$47,955.60
Owned After
200,814
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$16.30
Shares
1,272
Total Value
$20,733.60
Owned After
217,958
SEC Form 4
Chief Technology Officer
Avg Cost/Share
$16.30
Shares
1,585
Total Value
$25,835.50
Owned After
200,814
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Fromkin Andrew J. | IMVT | Director | Dec 1, 2025 | Sell | $23.55 | 22,249 | $517,189.24 | 88,750 | |
| Hughes Douglas J. | IMVT | Director | Dec 1, 2025 | Sell | $23.55 | 15,000 | $348,665.38 | 120,773 | |
| Gloria Melanie | IMVT | Chief Operating Officer | Nov 20, 2025 | Sell | $23.76 | 12,626 | $298,237.29 | 175,886 | |
| Geffner Michael | IMVT | Chief Medical Officer | Oct 22, 2025 | Sell | $19.03 | 2,595 | $49,382.85 | 217,958 | |
| Stout Jay S | IMVT | Chief Technology Officer | Oct 22, 2025 | Sell | $19.03 | 2,520 | $47,955.60 | 200,814 | |
| Geffner Michael | IMVT | Chief Medical Officer | Oct 8, 2025 | Sell | $16.30 | 1,272 | $20,733.60 | 217,958 | |
| Stout Jay S | IMVT | Chief Technology Officer | Oct 8, 2025 | Sell | $16.30 | 1,585 | $25,835.50 | 200,814 |
Compare IMVT vs Leading Stocks
See how IMVT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.